Neurologic Disorders and COVID-19: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) No edit summary |
|||
Line 51: | Line 51: | ||
==== 6. Myelosuppression ==== | ==== 6. Myelosuppression ==== | ||
<br /> | <br /> | ||
==References== | ==References== |
Revision as of 08:59, 25 June 2020
To go to the COVID-19 project topics list, click here.
COVID-19 Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Neurologic Disorders and COVID-19 On the Web |
American Roentgen Ray Society Images of Neurologic Disorders and COVID-19 |
Risk calculators and risk factors for Neurologic Disorders and COVID-19 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Rinky Agnes Botleroo, M.B.B.S.
Overview
Pathophysiology of the Complications in the Nervous System
Mechanism of targetting the Nervous System
Complications in the Central Nervous System
Cerebrovascular Accident/Stroke
- Hemorrhagic
- Ischaemic
Acute Encephalitis
Viral Meningitis
Epileptic Seizures
Encephalopathy
Headache
Complications in the Peripheral Nervous system
Guillain-Barre syndrome
Anosmia
Acute Myelitis
Miller Fischer Sydrome
Polyneuritis Cranialis
Complications due to medication interaction
1. Statin induced myotoxicity
- Myalgia, myopathies, rhabdomyolysis
2. 2nd and 3rd degree atrioventricular block
- Lopinavir/ Ritonavir (Kaltera) (400 mg/100 mg)
3. Prolong QTc interval
- Chloroquine/Hydroxychloroquine
4. Myelotoxicity
- Ribavirin
5. Prolonged PR interval
- Atazanavir
6. Myelosuppression